NPM1 and acute myeloid leukemia: Allogeneic stem cell transplantation (allo-SCT) may be included in the early phase of therapy for patients with intermediate- or high-risk cytogenetics or in patients who do not achieve CR with the initial induction therapy but is not recommended in patients with favorable risk, such as nucleophosmin-1 (NPM1)-mutated or core-binding factor AML [2,3,4,8].